在一个巨细胞瘤患者中,雷米马佐拉姆的严重过敏反应:一个病例报告
Julie Mani1, Amanda Strang2, Adeel A Faruki1
1Department of Anesthesiology and Perioperative Medicine, MD Anderson Cancer Center, Houston, USA.
Cureus
|October 11, 2024
概括
雷米马佐拉姆 (一种短效镇静剂) 后的过敏反应很少见,特别是在巨细胞疾病患者中. 这一案例突出显示了在乳腺细胞瘤患者中诊断过敏反应的方法.
科学领域:
- 麻醉学 麻醉学
- 药理学 药理学是指药理学的学科.
- 过敏和免疫学 过敏和免疫学
背景情况:
- 雷米马佐拉姆酸盐是一种新型,超短效的二,具有良好的安全性.
- 对雷米马佐拉姆的过敏反应很少被报告,并且以前没有记录在巨细胞疾病中.
- 巨细胞疾病涉及异常的巨细胞增殖,增加过敏风险.
研究的目的:
- 在患有巨细胞瘤的患者中报告罕见的雷米马佐拉姆诱导的过敏反应病例.
- 描述这种特定患者群体中过敏反应的诊断方法和治疗方法.
- 为了有助于了解患有潜在的巨细胞疾病的患者对新型麻醉剂的过敏反应.
主要方法:
- 一个77岁的男性患有瘤性巨细胞瘤的病例报告.
- 在医疗过程中使用雷米马佐拉姆.
- 监测不良反应,及时启动治疗.
- 通过血清三酶水平升高确认过敏反应.
主要成果:
- 患者经历过敏反应,出现呼吸短促,缺氧,意识丧失,心动减速和低血压.
- 随着弗卢马泽尼尔,德克萨米他,迪芬胺,法莫蒂丁和烯的使用,症状得到缓解.
- 血清三酶水平升高证实了过敏反应.
结论:
- 雷米马佐拉姆可以诱导过敏反应,即使在患有巨细胞疾病的患者中.
- 在这种情况下,早期识别和多剂治疗对于治疗过敏反应至关重要.
- 这一案例凸显了在发生乳腺细胞瘤患者对新药不良反应时考虑过敏反应的重要性.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
241
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
241
Allergic Reactions
27.3K
Overview
27.3K
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
179
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
179
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
151
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
151


